Cargando…

Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial

BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis su...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yujin, Ba, Zhaoyong, Roberts, Robert F., Rogers, Connie J., Fleming, Jennifer A., Meng, Huicui, Furumoto, Emily J., Kris-Etherton, Penny M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492721/
https://www.ncbi.nlm.nih.gov/pubmed/28662676
http://dx.doi.org/10.1186/s12937-017-0261-6
_version_ 1783247387404271616
author Lee, Yujin
Ba, Zhaoyong
Roberts, Robert F.
Rogers, Connie J.
Fleming, Jennifer A.
Meng, Huicui
Furumoto, Emily J.
Kris-Etherton, Penny M.
author_facet Lee, Yujin
Ba, Zhaoyong
Roberts, Robert F.
Rogers, Connie J.
Fleming, Jennifer A.
Meng, Huicui
Furumoto, Emily J.
Kris-Etherton, Penny M.
author_sort Lee, Yujin
collection PubMed
description BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis subsp. lactis BB-12(®) (BB-12(®)) (3.16 × 10(9) CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults. METHODS: In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18–40 years were randomly assigned to: 1) yogurt smoothie with no BB-12(®) (YS), 2) yogurt smoothie with BB-12(®) added pre-fermentation (PRE), 3) yogurt smoothie with BB-12(®) added post-fermentation (POST), 4) BB-12(®) containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period. RESULTS: Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003). CONCLUSIONS: BB-12(®) supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference. TRIAL REGISTRATION: This trial was registered at clinicaltrials.gov as NCT01399996.
format Online
Article
Text
id pubmed-5492721
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54927212017-06-30 Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial Lee, Yujin Ba, Zhaoyong Roberts, Robert F. Rogers, Connie J. Fleming, Jennifer A. Meng, Huicui Furumoto, Emily J. Kris-Etherton, Penny M. Nutr J Research BACKGROUND: Some probiotics have hypocholesterolemic effects in animal studies, which are mediated, in part, by increases in fecal short chain fatty acids (SCFAs). Clinical trials of probiotics on lipids/lipoproteins are inconsistent. OBJECTIVE: We examined the effects of Bifidobacterium animalis subsp. lactis BB-12(®) (BB-12(®)) (3.16 × 10(9) CFUs/day) on lipids and lipoproteins and fecal excretion of SCFAs in healthy adults. METHODS: In a randomized, partially blinded, 4-period, crossover study, 30 adults (11 men, 19 women) aged 18–40 years were randomly assigned to: 1) yogurt smoothie with no BB-12(®) (YS), 2) yogurt smoothie with BB-12(®) added pre-fermentation (PRE), 3) yogurt smoothie with BB-12(®) added post-fermentation (POST), 4) BB-12(®) containing capsule (CAP). We measured serum lipids/lipoproteins, glucose, insulin, C-reactive protein (CRP), and fecal SCFAs at baseline and after each treatment period. RESULTS: Total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides (TGs) did not differ after the PRE, POST, and CAP periods versus the YS or between treatments. Compared to baseline, fecal acetate was significantly increased after the YS (Δ = 211.89 ± 75.87 μg/g, P = 0.007) and PRE (Δ = 204.98 ± 75.70 μg/g, P = 0.009) periods. The percent increase in fecal acetate was significantly greater after the YS versus the POST period (52.2 ± 13.2% vs. 24.5 ± 13.2%, P = 0.023). Fecal total SCFAs, propionate and butyrate did not differ between treatment periods. Fecal total SCFAs were negatively associated with TC (r = -0.22, P = 0.01), LDL-C (r = -0.24, P = 0.004), age (r = -0.33, P < 0.001), and waist circumference (r = -0.25, P = 0.003). CONCLUSIONS: BB-12(®) supplementation did not improve lipids, lipoproteins and total and individual fecal SCFAs. Fecal SCFAs were negatively associated with TC, LDL-C, age, and waist circumference. TRIAL REGISTRATION: This trial was registered at clinicaltrials.gov as NCT01399996. BioMed Central 2017-06-29 /pmc/articles/PMC5492721/ /pubmed/28662676 http://dx.doi.org/10.1186/s12937-017-0261-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lee, Yujin
Ba, Zhaoyong
Roberts, Robert F.
Rogers, Connie J.
Fleming, Jennifer A.
Meng, Huicui
Furumoto, Emily J.
Kris-Etherton, Penny M.
Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title_full Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title_fullStr Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title_full_unstemmed Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title_short Effects of Bifidobacterium animalis subsp. lactis BB-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
title_sort effects of bifidobacterium animalis subsp. lactis bb-12(®) on the lipid/lipoprotein profile and short chain fatty acids in healthy young adults: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492721/
https://www.ncbi.nlm.nih.gov/pubmed/28662676
http://dx.doi.org/10.1186/s12937-017-0261-6
work_keys_str_mv AT leeyujin effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT bazhaoyong effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT robertsrobertf effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT rogersconniej effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT flemingjennifera effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT menghuicui effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT furumotoemilyj effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial
AT krisethertonpennym effectsofbifidobacteriumanimalissubsplactisbb12onthelipidlipoproteinprofileandshortchainfattyacidsinhealthyyoungadultsarandomizedcontrolledtrial